Novartis: launch of Morphosys drug by could be 2027 or later

Novartis’ (NOVN.S) CEO said on Thursday that the delayed launch of blood-cancer drug pelabresib from the takeover of Morphosys could be achieved in 2027 or later, but any approval would depend on further safety data.